These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25801495)

  • 1. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
    Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
    Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life.
    Shahnaz G; Iqbal J; Rahmat D; Perera G; Laffleur F; Rossi D; Bernkop-Schnürch A
    J Control Release; 2012 Feb; 157(3):375-82. PubMed ID: 21986100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery.
    Thambi T; You DG; Han HS; Deepagan VG; Jeon SM; Suh YD; Choi KY; Kim K; Kwon IC; Yi GR; Lee JY; Lee DS; Park JH
    Adv Healthc Mater; 2014 Nov; 3(11):1829-38. PubMed ID: 24753360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery.
    Son S; Rao NV; Ko H; Shin S; Jeon J; Han HS; Nguyen VQ; Thambi T; Suh YD; Park JH
    Int J Biol Macromol; 2018 Apr; 110():399-405. PubMed ID: 29133095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo.
    Gaowa A; Horibe T; Kohno M; Sato K; Harada H; Hiraoka M; Tabata Y; Kawakami K
    J Control Release; 2014 Feb; 176():1-7. PubMed ID: 24378440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate.
    Shahnaz G; Perera G; Sakloetsakun D; Rahmat D; Bernkop-Schnürch A
    J Control Release; 2010 May; 144(1):32-8. PubMed ID: 20117156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases.
    Gaowa A; Horibe T; Kohno M; Harada H; Hiraoka M; Kawakami K
    Clin Exp Metastasis; 2016 Jan; 33(1):87-95. PubMed ID: 26467564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending insulin action in vivo by conjugation to carboxymethyl dextran.
    Baudys M; Letourneur D; Liu F; Mix D; Jozefonvicz J; Kim SW
    Bioconjug Chem; 1998; 9(2):176-83. PubMed ID: 9548532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pH-responsive carboxymethyl dextran-based conjugate as a carrier of docetaxel for cancer therapy.
    Han HS; Lee M; An JY; Son S; Ko H; Lee H; Chae YS; Kang YM; Park JH
    J Biomed Mater Res B Appl Biomater; 2016 May; 104(4):789-96. PubMed ID: 26687579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional disulfide-based cationic dextran conjugates for intravenous gene delivery targeting ovarian cancer cells.
    Song Y; Lou B; Zhao P; Lin C
    Mol Pharm; 2014 Jul; 11(7):2250-61. PubMed ID: 24892216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete regression of xenografted breast tumors by dextran-based dual drug conjugates containing paclitaxel and docosahexaenoic acid.
    Wang S; Liu J; Lv H; Huang X; Dong P; Wang Q; Yang H; Wang S; Li X; Hu J; Wang D; Cao S; Xie L; Shi Y
    Eur J Med Chem; 2022 Oct; 240():114567. PubMed ID: 35779290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models.
    Chau Y; Padera RF; Dang NM; Langer R
    Int J Cancer; 2006 Mar; 118(6):1519-26. PubMed ID: 16187287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
    Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
    Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
    Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
    Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.
    Tada N; Horibe T; Haramoto M; Ohara K; Kohno M; Kawakami K
    Biochem Biophys Res Commun; 2011 Apr; 407(2):383-8. PubMed ID: 21396910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Tumor Penetration of Podophyllotoxin-Carboxymethylcellulose Conjugates with Various Chemical Compositions in Tumor Spheroid Culture and In Vivo Solid Tumor.
    Yang Y; Roy A; Zhao Y; Undzys E; Li SD
    Bioconjug Chem; 2017 May; 28(5):1505-1518. PubMed ID: 28437080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
    Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
    Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
    Yang L; Horibe T; Kohno M; Haramoto M; Ohara K; Puri RK; Kawakami K
    Mol Cancer Ther; 2012 Jan; 11(1):235-43. PubMed ID: 22084165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.